Body composition and cardiometabolic risk reduction following therapy with a multi-ingredient nutraceutical formulation: a real-life clinical study.

BACKGROUND

Women in perimenopause or postmenopause experience an increased susceptibility to cardiometabolic disorders due to hormonal and physiological changes. This study assessed the effects of a multi-ingredient nutraceutical formulation (Syndrema®, Ghimas S.p.A.) on metabolic, inflammatory and anthropometric parameters in at-risk women in perimenopause. The formulation was designed to simultaneously target several components: body fat mass, insulin resistance, dyslipidaemia, glycaemic homeostasis, arterial hypertension and oxidative stress.

METHODS

Twenty-four women in perimenopause or postmenopause (aged 45-60 years, BMI ≥27) participated in a 90-day prospective, single-arm observational study conducted in a real-life clinical setting. They received the nutraceutical alongside an isocaloric diet and a standardized physical activity regimen. Assessments of clinical, biochemical and body composition parameters were conducted at baseline and at the 90-day follow-up. Evaluations included anthropometrics, bioelectrical impedance analysis, lipid profile, inflammatory and metabolic markers, insulin and glucose levels and haemodynamic variables. Paired t-tests were used to evaluate changes over time.

RESULTS

After 90 days, participants showed significant reductions in body weight, body mass index, waist circumference, systolic blood pressure, low density lipoprotein cholesterol, triglycerides, C-reactive protein, homocysteine and uric acid. Bioelectrical impedance analysis indicated improved body composition with reductions in fat mass and fat mass percentage. Liver enzymes and azotaemia also declined, suggesting systemic benefits.

CONCLUSIONS

The combination of a multi-ingredient nutraceutical and lifestyle modifications was associated with favourable changes in cardiometabolic, inflammatory and body composition parameters in women in perimenopause and postmenopause. These results support the role of early, non-pharmacological interventions in mitigating cardiometabolic risk during menopause. Further randomized controlled trials are needed to confirm efficacy and long-term outcomes.